LVM Capital Management Ltd. MI Increases Stock Holdings in Pfizer Inc. $PFE

by · The Markets Daily

LVM Capital Management Ltd. MI boosted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 2.7% during the 2nd quarter, HoldingsChannel reports. The firm owned 321,855 shares of the biopharmaceutical company’s stock after purchasing an additional 8,571 shares during the period. LVM Capital Management Ltd. MI’s holdings in Pfizer were worth $7,802,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the period. Triumph Capital Management raised its stake in shares of Pfizer by 20.0% in the fourth quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 1,717 shares during the period. Janus Henderson Group PLC raised its stake in shares of Pfizer by 80.7% in the fourth quarter. Janus Henderson Group PLC now owns 958,315 shares of the biopharmaceutical company’s stock worth $25,434,000 after buying an additional 427,886 shares during the period. Finally, ProShare Advisors LLC raised its stake in shares of Pfizer by 15.0% in the fourth quarter. ProShare Advisors LLC now owns 904,859 shares of the biopharmaceutical company’s stock worth $24,006,000 after buying an additional 118,216 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Jefferies Financial Group lifted their target price on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Finally, Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.12.

Check Out Our Latest Stock Report on Pfizer

Pfizer Stock Performance

NYSE PFE opened at $23.91 on Friday. The stock has a market capitalization of $135.94 billion, a PE ratio of 12.72, a P/E/G ratio of 0.88 and a beta of 0.55. The business has a 50 day simple moving average of $24.79 and a two-hundred day simple moving average of $24.30. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).